Trial Profile
A Single Ascending Dose and Multiple Ascending Dose Phase I Study of PXS-5382A Administered Orally in Healthy Male Adult Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Jan 2024
Price :
$35
*
At a glance
- Drugs PXS-5382A (Primary)
- Indications Hepatic fibrosis; Idiopathic pulmonary fibrosis; Non-alcoholic steatohepatitis; Renal fibrosis
- Focus Adverse reactions
- Sponsors Pharmaxis; Synairgen; Syntara Limited
- 04 Dec 2023 According to a Syntara Limited media release, Pharmaxis has changed its name to Syntara Limited
- 15 Nov 2018 Results published in the Media Release
- 14 Nov 2018 Status changed from active, no longer recruiting to completed, according to an Arix Bioscience media release.